Holen Sie sich die Stockscreener-App
55.28
1.06%
-0.59
Handel nachbörslich:
54.53
-0.75
-1.36%
Schlusskurs vom Vortag:
$55.87
Offen:
$55.46
24-Stunden-Volumen:
446.10K
Relative Volume:
0.77
Marktkapitalisierung:
$2.88B
Einnahmen:
$15.13M
Nettoeinkommen (Verlust:
$-44.05M
KGV:
-33.91
EPS:
-1.63
Netto-Cashflow:
$-47.75M
1W Leistung:
+1.97%
1M Leistung:
+22.79%
6M Leistung:
-14.67%
1J Leistung:
+716.54%
1-Tages-Spanne:
$54.01
$56.14
1-Wochen-Bereich:
$52.40
$58.06
52-Wochen-Spanne:
$5.65
$65.60
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
Nisa Investment Advisors LLC Increases Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Trading Up 6.3%What's Next? - MarketBeat
How to Take Advantage of moves in (JANX) - Stock Traders Daily
Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors - Barron's
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $66.44 - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Janux Therapeutics CEO sells shares worth $1.34 million By Investing.com - Investing.com Australia
Janux Therapeutics CEO sells shares worth $1.34 million - Investing.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat
This Insider Has Just Sold Shares In Janux Therapeutics - Simply Wall St
Warren Buffett Back for More, Plus Big Insider Buying at Biotechs Too - 24/7 Wall St.
Janux Therapeutics (NASDAQ:JANX) Coverage Initiated at UBS Group - Defense World
Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World
UBS Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation - MSN
Janux therapeutics sees significant stock sale by major shareholder Jay Lichter for $178,084 - Investing.com
Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials - openPR
Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics - Barchart
Janux Therapeutics stock offers upside on T cell engager platform, says UBS - Investing.com Canada
Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics - Benzinga
Janux Therapeutics (NASDAQ:JANX) Receives New Coverage from Analysts at UBS Group - MarketBeat
Paradigm Biocapital Advisors LP Acquires Shares in Janux Therape - GuruFocus.com
RA Capital Management Reduces Stake in Janux Therapeutics - GuruFocus.com
Insider Buying: Janux Therapeutics, Inc. (NASDAQ:JANX) Director Purchases 1,200,000 Shares of Stock - MarketBeat
Ra Capital Management buys $53.7 million in Janux Therapeutics stock By Investing.com - Investing.com South Africa
Ra Capital Management buys $53.7 million in Janux Therapeutics stock - Investing.com
Vanguard S&P 500 Growth ETF (NYSEARCA:VOOG) Shares Sold by Cwm LLC - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by SG Americas Securities LLC - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 1,843 Shares - MarketBeat
Janux therapeutics sees $23.8 million in stock sales By Investing.com - Investing.com Australia
Janux therapeutics sees $23.8 million in stock sales - Investing.com
AQR Capital Management LLC Invests $215,000 in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
10 Best Small-Cap Stocks to Buy for 2025 | Investing - U.S News & World Report Money
Janux Therapeutics (NASDAQ:JANX) Shares Down 3.6%Time to Sell? - MarketBeat
How should investors view Janux Therapeutics Inc (JANX)? - US Post News
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business - Yahoo Finance
Monopar Therapeutics Expands Portfolio with New Patent Filing - Yahoo Finance
Janux Therapeutics Inc: Navigating Market Fluctuations with a 2.75B Market Cap - The InvestChronicle
Janux Therapeutics (NASDAQ:JANX) Stock Price Up 6.6%Time to Buy? - MarketBeat
Prostate Cancer Clinical Trial Pipeline Experiences - GlobeNewswire
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit - Yahoo Finance
Janux Therapeutics Inc [JANX] Investment Appeal on the Rise - Knox Daily
Millennium Management LLC Purchases 11,281 Shares of DT Midstream, Inc. (NYSE:DTM) - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
Dimensional Fund Advisors LP Increases Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
(JANX) Trading Signals - Stock Traders Daily
How to interpret Janux Therapeutics Inc (JANX)’s stock chart patterns - US Post News
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Foghorn Therapeutics Unveils Clinical Pipeline Progress - Yahoo Finance
Janux Therapeutics Inc [JANX] Stock sold by Insider Avalon Ventures XI, L.P. for $5.18 million - Knox Daily
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):